-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades LAVA Therapeutics to Neutral, Lowers Price Target to $1.5

Benzinga·02/27/2025 13:53:05
Listen to the news
HC Wainwright & Co. analyst Arthur He downgrades LAVA Therapeutics (NASDAQ:LVTX) from Buy to Neutral and lowers the price target from $2 to $1.5.